According to Zacks, “BrainsWay Ltd. is a commercial stage medical device company. It is focused on the development and sale of non-invasive neuromodulation products using the Company’s proprietary Deep Transcranial Magnetic Stimulation technology for the treatment of major depressive disorder and obsessive-compulsive disorder. BrainsWay Ltd. is based in Jerusalem, Israel. “
BWAY has been the subject of a number of other research reports. Raymond James reaffirmed a “neutral” rating and issued a $35.00 price objective on shares of Stantec in a report on Monday, May 13th. Cantor Fitzgerald assumed coverage on CytomX Therapeutics in a research note on Monday, May 13th. They set an “overweight” rating and a $21.00 price target on the stock. LADENBURG THALM/SH SH downgraded PennantPark Investment from a “buy” rating to a “neutral” rating in a research note on Monday, May 13th. Oppenheimer upped their price target on Novavax from $1.25 to $25.00 in a research note on Monday, May 13th. Finally, CIBC upped their price target on NorthWest Health Prop Real Est Inv Trust from C$11.75 to C$12.00 in a research note on Monday, May 13th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $15.80.
BRAINSWAY LTD/S stock traded down $0.10 during mid-day trading on Tuesday, hitting $10.00. The stock had a trading volume of 3,200 shares, compared to its average volume of 14,387. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.33 and a current ratio of 1.33. The company has a 50 day moving average of $9.93. BRAINSWAY LTD/S has a one year low of $8.00 and a one year high of $12.39.
BRAINSWAY LTD/S (NASDAQ:BWAY) last issued its earnings results on Wednesday, May 29th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.02. The firm had revenue of $5.18 million during the quarter, compared to the consensus estimate of $5.00 million. Analysts forecast that BRAINSWAY LTD/S will post -0.43 EPS for the current year.
About BRAINSWAY LTD/S
Brainsway Ltd. engages in the development and provision of technology solutions for non-invasive treatment of brain disorders in Israel and internationally. It offers deep transcranial magnetic stimulation systems for treating various conditions, including autism, Alzheimer's disease, bipolar disorders, chronic pains, depressive disorders, Parkinson's diseases, schizophrenia, smoking cessation, post-traumatic stress disorders, multiple sclerosis, obsessive compulsive disorders, and stroke rehabilitation.
Recommended Story: What is Call Option Volume?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BRAINSWAY LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BRAINSWAY LTD/S and related companies with MarketBeat.com's FREE daily email newsletter.